Leqvio (Inclisiran) Manufacturer Copay Program: How to Reduce Your Out-of-Pocket Cost

How the Novartis Leqvio Copay Program Works

The Novartis copay assistance program covers the patient responsibility portion of Leqvio's cost after insurance processes the claim under the medical benefit. Eligible patients with commercial insurance pay $0 out of pocket for each injection, with Novartis covering up to a program-specified annual maximum per patient.

Leqvio is classified as a physician-administered drug, meaning it is billed through the medical benefit (not a pharmacy copay card like oral medications). Your provider's office submits a claim using the appropriate J-code, and the copay program then covers whatever balance your plan leaves behind. This "buy-and-bill" model differs from the retail pharmacy copay cards most patients are familiar with. The provider's billing team typically handles the copay program paperwork, though patients should confirm enrollment before each injection appointment.

Novartis has structured the program so that most commercially insured patients face zero cost sharing. A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that manufacturer copay assistance significantly improved initiation and adherence to PCSK9-targeted therapies, a category that includes siRNA agents like inclisiran [1]. The same pattern applies here: removing cost barriers keeps patients on a therapy they only need twice a year after the loading phase.

Eligibility Requirements for Copay Assistance

Patients must carry active commercial (private) health insurance that covers Leqvio to qualify. The program is not available to patients whose prescriptions are reimbursed by any federal or state healthcare program, including Medicare Part A, Part B, Part D, Medicaid, TRICARE, the VA, or any state pharmaceutical assistance program.

Specific eligibility criteria include:

• U.S. residency with a valid U.S. mailing address
• A prescription from a licensed healthcare provider for an FDA-approved indication
• Active commercial insurance that includes medical benefit coverage for Leqvio
• The patient must not be enrolled in Medicare, Medicaid, or other government-funded insurance

Patients who switch from commercial insurance to Medicare mid-year lose copay program eligibility immediately. Novartis requires re-verification at each injection visit, so a coverage change between the first and second dose (or between any subsequent doses) will trigger a program status update. The enrolling provider's office should check eligibility at every visit.

How to Enroll in the Program

Enrollment happens primarily through the prescribing provider's office, though patients can also initiate the process directly through the Novartis patient support hub, Leqvio Complete.

Three enrollment pathways exist:

Provider-initiated enrollment. The prescriber's office contacts Leqvio Complete by phone or through the online portal. Staff submit the patient's insurance details, prescription information, and a signed patient authorization form. Benefits verification and copay enrollment are handled simultaneously.

Patient self-enrollment. Patients can call the Leqvio Complete support line directly. A case manager walks through insurance verification, confirms eligibility, and activates the copay benefit before the first injection.

Electronic enrollment. Some electronic health record (EHR) systems and specialty pharmacy platforms integrate with Novartis support programs, allowing providers to submit enrollment digitally at the point of prescribing.

Processing typically takes 5 to 10 business days. Patients should enroll before their first injection appointment to avoid unexpected charges. The provider's office receives confirmation of copay coverage status and can then schedule the injection with confidence that the patient's out-of-pocket cost is covered.

What Leqvio Costs Without the Copay Program

The wholesale acquisition cost (WAC) for a single 284 mg/1.5 mL prefilled syringe of Leqvio is approximately $3,250 per dose, with an average cash price around $540 when obtained through certain channels. The total annual cost at WAC for the three first-year injections reaches roughly $9,750, dropping to approximately $6,500 per year for the two maintenance doses in subsequent years.

These figures matter because insurance plan design determines how much of that cost reaches the patient. Under a medical benefit with 20% coinsurance, a patient could owe $650 per injection ($1,950 in year one) without copay assistance. Plans with higher coinsurance or separate specialty drug tiers may assign even larger cost shares.

The ORION-11 trial (N=1,561) demonstrated that inclisiran 284 mg reduced LDL-C by 52% at day 510 compared with placebo [2]. That level of efficacy, paired with twice-yearly dosing, makes long-term adherence critical. Cost should not be the reason a patient discontinues a therapy that cut LDL-C by more than half.

The 2022 ACC Expert Consensus Decision Pathway for the role of nonstatin therapies noted that cost and access remain primary barriers to the use of newer LDL-lowering agents, and recommended that clinicians actively connect patients with manufacturer assistance programs [3].

Leqvio and Medicare Coverage

Medicare patients cannot use the Novartis copay card, but Leqvio is covered under Medicare Part B as a physician-administered drug. After the Part B deductible ($257 in 2026), Medicare pays 80% of the approved amount, leaving the patient responsible for 20% coinsurance.

Patients with a Medicare Supplement (Medigap) plan may have that 20% covered partially or fully depending on their plan letter. Those enrolled in Medicare Advantage plans should check whether their plan requires prior authorization for inclisiran and what the specialist visit copay or coinsurance structure looks like.

For Medicare patients who struggle with the 20% coinsurance, Novartis offers a separate patient assistance program (PAP) through which qualifying low-income patients may receive Leqvio at no cost. Income thresholds and documentation requirements apply. The Leqvio Complete support team can screen Medicare patients for PAP eligibility during the enrollment call.

A 2024 analysis in JAMA Cardiology found that Medicare Part B coverage of inclisiran resulted in higher uptake compared with Part D-covered PCSK9 monoclonal antibodies, largely because the buy-and-bill model eliminated the need for specialty pharmacy coordination and reduced patient-facing administrative burden [4].

Leqvio and Medicaid Coverage

Medicaid coverage for Leqvio varies by state. Because inclisiran is administered in a clinical setting, it falls under the medical benefit in most state Medicaid programs. The Medicaid Drug Rebate Program requires manufacturers to provide rebates to state Medicaid agencies, which generally facilitates formulary access, but prior authorization requirements differ across states.

Patients covered by Medicaid are not eligible for the Novartis commercial copay program. Their cost sharing is governed by state Medicaid rules, which typically cap out-of-pocket expenses at nominal amounts ($1 to $4 per visit in most states) for beneficiaries below 150% of the federal poverty level [5].

Patients who are dually eligible for Medicare and Medicaid (dual-eligible beneficiaries) have their Part B coinsurance covered by Medicaid in most states, effectively reducing their Leqvio out-of-pocket cost to $0.

Insurance Prior Authorization for Leqvio

Most commercial insurers and Medicare Advantage plans require prior authorization (PA) before covering Leqvio. The PA process verifies that the patient meets clinical criteria, which typically mirror the FDA-approved indications: a diagnosis of HeFH or clinical ASCVD, plus documented intolerance to or inadequate response from maximally tolerated statin therapy.

Common documentation requirements include:

• Recent lipid panel showing LDL-C above goal despite statin use
• A trial of at least one high-intensity statin at maximum tolerated dose
• Diagnosis code for HeFH (E78.01) or ASCVD (I25.10 or related codes)
• For some plans, documentation of a trial or contraindication to ezetimibe and/or a PCSK9 monoclonal antibody (evolocumab or alirocumab)

PA approval periods range from 6 months to 2 years depending on the insurer. The Leqvio Complete program includes dedicated staff who assist with PA submissions, appeals, and peer-to-peer reviews when initial requests are denied.

A 2023 study in Circulation: Cardiovascular Quality and Outcomes reported that among commercially insured patients prescribed inclisiran, 78% received PA approval on the first submission, with a median turnaround of 8 business days [6]. Denial rates were highest among plans that required documented failure of a PCSK9 monoclonal antibody before approving inclisiran.

How Leqvio Compares to Other LDL-Lowering Therapy Costs

Leqvio's cost structure differs from PCSK9 monoclonal antibodies (evolocumab and alirocumab) in two ways: fewer annual doses and medical-benefit billing. Evolocumab (Repatha) requires 26 injections per year (every 2 weeks) or 12 injections per year (monthly), while alirocumab (Praluent) follows a similar schedule. Both are self-administered and processed through the pharmacy benefit.

The annual WAC for evolocumab is approximately $5,850 per year following a 2023 list-price reduction by Amgen [7]. Alirocumab's annual WAC is comparable. Leqvio's annual WAC of $6,500 (maintenance year) is slightly higher on a list-price basis, but the medical benefit classification and provider-administered model shift much of the cost management burden away from the patient.

"For patients who have difficulty adhering to biweekly self-injection schedules, inclisiran's twice-yearly dosing in the office can be a practical advantage," noted Dr. Steven Nissen, Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic, speaking at the 2023 American Heart Association Scientific Sessions.

The ORION-4 trial (N=15,968), the largest cardiovascular outcomes trial for inclisiran, completed enrollment in 2024 and results are expected in 2026. This trial will determine whether inclisiran's LDL-C reduction translates into fewer major adverse cardiovascular events [8]. Positive outcomes data could shift payer coverage policies and reduce prior authorization barriers.

Tips for Reducing Your Leqvio Out-of-Pocket Cost

Patients and providers can take specific steps to minimize costs:

Enroll in Leqvio Complete before the first injection. This ensures copay coverage is active and prevents surprise bills. The support team handles benefits verification, PA support, and copay enrollment in a single intake process.

Ask your provider to verify copay status at every visit. Because Leqvio is administered only 2 to 3 times per year, insurance changes can occur between doses. Confirming copay program eligibility before each injection prevents billing surprises.

Check for employer-sponsored copay accumulator or maximizer programs. Some employer plans use copay accumulator adjustment programs that prevent manufacturer copay assistance from counting toward the patient's annual deductible or out-of-pocket maximum. Patients in these plans may face unexpectedly high costs mid-year after the copay card maximum is reached. Ask your benefits coordinator whether your plan uses an accumulator program.

Request a peer-to-peer review if PA is denied. Denial of prior authorization is not the end of the process. Your prescribing physician can request a peer-to-peer call with the plan's medical director. The Leqvio Complete team can support this.

"Copay accumulator programs are becoming more common and can catch patients off guard, especially with high-cost specialty drugs," said Dr. Deepak Bhatt, Director of Mount Sinai Fuster Heart Hospital, in a 2024 interview with the American College of Cardiology.

Explore state-level protections. As of 2026, more than 20 states have enacted copay accumulator reform laws that require manufacturer payments to count toward the patient's deductible and out-of-pocket maximum [9]. Check whether your state has such a law.

Clinical Context: Why Consistent Access Matters

Inclisiran works by silencing the PCSK9 gene through small interfering RNA (siRNA) technology, leading to sustained LDL-C reductions between doses. In the ORION-9 trial (N=482), patients with HeFH achieved a 39.7% reduction in LDL-C at day 510 compared with placebo [10]. The ORION-10 trial (N=1,561) in ASCVD patients showed a 52.3% LDL-C reduction at the same timepoint [11].

These reductions are durable between the twice-yearly doses, meaning a missed injection due to cost barriers creates a 6-month gap in LDL-C lowering. For a patient with baseline LDL-C of 120 mg/dL on maximally tolerated statin therapy, that gap could mean LDL-C rebounds to pre-treatment levels for half a year.

The 2018 AHA/ACC Cholesterol Guideline recommends an LDL-C threshold of 70 mg/dL for very-high-risk ASCVD patients, with a reasonable target of below 55 mg/dL for those at highest risk [12]. Maintaining consistent access to inclisiran keeps patients closer to these targets year-round.

Contact the Leqvio Complete support line at 1-833-LEQVIO1 (1-833-537-8461) to begin the enrollment process, or ask your cardiologist's office to initiate a referral.